Program
RAY121
A development code.
In Hoffmann-La Roche's pipeline, anti-C1s recycling antibody
. Its studies are mostly in Antiphospholipid Syndrome, led by Hoffmann-La Roche.
Furthest: phase 1, since Apr 4, 20242 company-led studies, 2 open or runningNext primary completion: Mar 31, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 22 open or running | phase 1since Apr 4, 2024 | Apr 4, 2024 | Mar 31, 2027phase 1 · NCT06371417 |
- Named in Hoffmann-La Roche’s own pipeline as
CHU anti-C1s recycling antibody
, phase 1, as of Oct 22, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 4, 2024First study: phase 1 study in Antiphospholipid SyndromeFirst studyNCT06371417 · 144 planned · United States, Australia, Austria and more
- Nov 27, 2024Phase 1 study in Antiphospholipid SyndromeNCT06723106 · 144 planned · Australia, Austria, Bulgaria and more
Ahead
- Mar 31, 2027Primary completion: phase 1 study in Antiphospholipid SyndromeNCT06371417
- Feb 28, 2028Primary completion: phase 1 study in Antiphospholipid SyndromeNCT06723106
TargetBeta
“anti-C1s recycling antibody”the company's pipeline, read by Claude · source
Other programs on C1S
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| riliprubart | Sanofi | phase 3 | 8 |
| SAR446597 | Sanofi | phase 2 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06723106Antiphospholipid Syndrome · Australia, Austria, Bulgaria and more | 1 | By invitation | Feb 28, 2028 | 144 |
| NCT06371417Antiphospholipid Syndrome · United States, Australia, Austria and more | 1 | Recruiting | Mar 31, 2027 | 144 |
How it is read
Names in the registry
- “RAY121”, 2 entries
Codes read as this program: RAY121.
Conditions, from the studies’ own filings
- Antiphospholipid Syndrome, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.